There are several studies that enroll patients with breast cancer into different stages to receive VGX-3100, a vaccine that targets HPV types 16 and 18; INO-9012, a DNA construct that induces human interleukin 12 (IL-12); ADXS11-001, a vaccine against the E7 protein made by HPV; MEDI4736, a PD-L1 inhibitor; a pNGVL4a/ E7 (Detox)/ HSP70 DNA vaccine in patients with HPV16+ cervical intraepithelial neoplasia, a combination with imiquimod (an innate immune activator) [18]. This evidence concerns the gene CD274 and breast carcinoma.